Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be reporting earnings this Wednesday after market close.

Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A ...

Analysts anticipate Exact Sciences to report an earnings per share (EPS) of $0.02. Anticipation surrounds Exact Sciences's ...

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced an expanded ...

LaMontagne will lead the commercial rollout of the company’s groundbreaking early-stage cancer detection test, Certitude.

Exact Sciences (EXAS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results ...

Colonoscopy prevalence increased from 19.5% in 2019 and 17.8% in 2021 to 27.7% in 2023, while stool-based testing increased ...

University research in Wisconsin led to $500 million Third Wave business, screening tests for cancer, including Cologuard ...

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.45 per share a year ago. These ...

After months of silence, Darksiders 4 is finally coming out of the shadows. During the THQ Nordic show, we received the first ...

Review quarterly and annual revenue, net income, and cash flow for Exact Sciences Corp (EXAS:XNAS) stock through the last fiscal year.